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OBJECTIVE—We investigated the function of the Prep1 gene in
insulin-dependent glucose homeostasis in liver.
RESEARCH DESIGN AND METHODS—Prep1 action on in-
sulin glucoregulatory function has been analyzed in liver of
Prep1-hypomorphic mice (Prep1
i/i), which express 2–3% of
Prep1 mRNA.
RESULTS—Based on euglycemic hyperinsulinemic clamp stud-
ies and measurement of glycogen content, livers from Prep1
i/i
mice feature increased sensitivity to insulin. Tyrosine phosphor-
ylation of both insulin receptor (IR) and insulin receptor sub-
strate (IRS)1/2 was signiﬁcantly enhanced in Prep1
i/i livers
accompanied by a speciﬁc downregulation of the SYP and SHP1
tyrosine phosphatases. Prep1 overexpression in HepG2 liver
cells upregulated SYP and SHP1 and inhibited insulin-induced IR
and IRS1/2 phosphorylation and was accompanied by reduced
glycogen content. Consistently, overexpression of the Prep1
partner Pbx1, but not of p160MBP, mimicked Prep1 effects on
tyrosine phosphorylations, glycogen content, and on SYP and
SHP1 expression. In Prep1 overexpressing cells, antisense silenc-
ing of SHP1, but not that of SYP, rescued insulin-dependent IR
phosphorylation and glycogen accumulation. Both Prep1 and
Pbx1 bind SHP1 promoter at a site located between nucleotides
2,113 and 1,778. This fragment features enhancer activity and
induces luciferase function by 7-, 6-, and 30-fold, respectively, in
response to Prep1, Pbx1, or both.
CONCLUSIONS—SHP1, a known silencer of insulin signal, is a
transcriptional target of Prep1. In liver, transcriptional activation
of SHP1 gene by Prep1 attenuates insulin signal transduction and
reduces glucose storage. Diabetes 60:138–147, 2011
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rep1 is an homeodomain transcription factor of
the three-amino acid loop extension (TALE) su-
perclass of proteins (1) that dimerizes with Pbx1,
enhancing target speciﬁcity and modulating tran-
scription regulatory function (2–8). Prep1 is essential for
embryonic development. Indeed, Prep1 null embryos die
before gastrulation (L.C. Fernandez-Diaz and F.B., unpub-
lished observations), whereas Prep1- hypomorphic mu-
tant mouse (Prep1
i/i) embryos, which express 2 to 3% of
Prep1 mRNA and up to 10% of the protein, show a leaky
embryonic-lethal phenotype and defects in angiogenesis,
hematopoiesis, and eye development. Part of the Prep1
i/i
phenotype depends on reduction of the Pbx protein level
(9–11).
In addition to Pbx, Prep1 also interacts with p160MBP in
competition with Pbx (12), preventing its proteosomal
degradation and enhancing its regulatory effect on PGC-1
and hence on its regulation on glucose metabolism (13).
The few surviving Prep1
i/i and the heterozygous Prep1
i/
mice show decreased insulin and glucagon production,
prolonged insulin response, and protection from insulin-
deﬁcient diabetes. This phenotype is due to a complex
tissue-speciﬁc mechanism. At the skeletal muscle level,
the enhanced insulin sensitivity was due to a decrease in
p160MBP, resulting in activation of PGC-1, overexpres-
sion of GLUT4, and increased glucose uptake (13). On the
other hand, the level of Pbx1 was not changed, which
drastically increases the Pbx/p160 ratio. Different mecha-
nism must operate in liver since Pbx1 and p160MBP are
expressed at different levels compared with skeletal
muscle.
Liver gluconeogenesis depends on the enzymes G6Pase
and PEPCK, the expression of which requires PGC-1 as
well as other transcription factors, including Foxo1 (14–
17). For example, in liver, glucagon induces G6Pase and
PEPCK and activates gluconeogenesis via PGC-1 (14).
This agrees with the Prep1
i/i phenotype that includes
smaller pancreas and reduced glucagon-circulating levels
(13). Whether and how Prep1 affects glucose metabolism
in liver is unknown at the present, but must be clariﬁed to
elucidate how Prep1 regulates insulin-dependent glucose
metabolism at the whole-body level. Indeed, PGC-1 up-
regulation in Prep1-deﬁcient mice is expected to produce
sustained gluconeogenesis. In contrast, these animals fea-
ture normal glucose tolerance and protection from
diabetes.
In liver, insulin-dependent glucoregulatory function is
controlled by a number of different mechanisms. Among
these, the function of several protein tyrosine phospha-
tases has been reported to play a major role. PTP1B, SYP,
and SHP1, for example, are known to negatively modulate
insulin action on liver glucose metabolism through ty-
rosine dephosphorylation of the insulin receptor and/or
IRS (18–20). At variance, the ubiquitously expressed cyto-
solic SHP2 phosphatase was described to positively mod-
ulate insulin signaling (21,22). Thus, the balance of these
individual phosphatases represents an important determi-
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maintained at the physiologic and molecular levels has
been only partially elucidated.
In the present work, we have focused on Prep1 action
on hepatic glucose metabolism. We show that in liver,
Prep1 restrains insulin action by activating transcription of
the SHP1 tyrosine phosphatase gene and inhibiting insulin
receptor and IRS signaling.
RESEARCH DESIGN AND METHODS
Materials. Media, sera, antibiotics for cell culture, and the lipofectamine
reagent were from Invitrogen (Grand Island, NY). The anti-Prep1 polyclonal
antibody and pBOS-Prep1, pSG5-Pbx1, PSG5-Prep1HR1, pRUFneo-p160 vec-
tors have been described previously (12,13). The PGC-1, actin, IR, Pbx1, Syp,
SHP1, PTP1B, G6Pase, and PEPCK antibodies were from Santa Cruz Biotech-
nology (Santa Cruz, CA). The pY, IRS1, and IRS2 antibodies were from Upstate
Biotechnolgy (Lake Placid, NY). The p160 antibody was from Zymed Labora-
tories (San Francisco, CA). Protein electrophoresis reagents were from
Bio-Rad (Richmond, VA), Western blotting and enhanced chemiluminescence
(ECL) reagents from Amersham Biosciences (Arlington Heights, IL). All other
chemicals were from Sigma (St. Louis, MO).
Studies in mice. High-fat diet treatment of C57BL/6J mice was performed as
described by Vigliotta et al. (23). Prep1-targeted mice were generated by gene
trapping (Lexikon Genetics, The Woodlands, TX). Their general phenotype
has been previously described (10,11). Weight of Prep1
i/ mice was slightly
lower than that of their nonhypomorphic littermates (13). All animal handling
conformed to regulations of the Ethics Committee on Animal Use of H.S.
Raffaele (Institutional Animal Care and Use Committee, permission number
207). Genotyping strategy has been previously described (13).
Hepatic tissue samples were collected rapidly after mice were killed with
a pentobarbitone overdose. Tissues were snap frozen in liquid nitrogen and
stored at 80°C for subsequent Western blotting as previously described (13).
Cell culture procedures and transfection. The HepG2 hepatocarcinoma
cells and NMuLi mouse liver cells were cultured at 37°C in Dulbecco’ s
modiﬁed Eagle’ s medium (DMEM) supplemented with 10% FCS, 2% L-
glutamine, 10,000 units/ml penicillin, and 10,000 g/ml streptomycin. Tran-
sient transfection of Prep1, Prep1HR1, p160 and Pbx1 plasmids or Syp (5-
CTCCGCGATGTCATGTTCCT-3) and SHP1 (5- GAGGTCTCGGTGAAAC
CACCT CACCATCCT-3) phosphorothioate antisense oligonucleotides or
scrambled control oligonucleotides Syp (5- TCGCCACGTCGCTCATTGTT-3)
and SHP1 (5-GTAGAGTTCCGTGAGACACCTCTCCACCAC-3) were per-
formed by the Lipofectamine method according to the manufacturer’s instruc-
tion. In stable transfection studies, individual G418-resistant clones were
selected by the limiting dilution technique (G418 effective dose, 0.8 mg/ml).
The expression of Prep1 by the individual clones was quantitated by Western
blotting. In both transient and stable transfection, the efﬁciency was consis-
tently between 65 and 75%.
Determination of glycogen content and triglycerides levels. Glycogen
was isolated from liver tissue or HepG2 cells homogenized in 0.1% SDS,
saturated with Na2SO4 for 30 at 37°C, followed by ethanol (EtOH) precipita-
tion. Glycogen content was determined as previously described (24,25).
The triglyceride content was extracted from frozen liver tissues and
determined as described previously (25).
Euglycemic-hyperinsulinemic clamps. Six-month-old male mice were cath-
eterized via the right internal jugular vein under isoﬂorane anesthesia. After
loss of pedal and corneal reﬂexes was assured, a catheter (platinum-cured
silicone tubing, 0.020 internal diameter  0.037 outer diameter; Harvard
Apparatus, Holliston, MA) was inserted into the right internal jugular and
advanced to the level of the superior vena cava. The catheter was ﬁlled with
saline, tunneled, and left in a subcutaneous pocket at the back of the neck. A
6-0 silk suture was attached to the free end of the catheter and exteriorized in
such a fashion as to allow retrieval of the catheter on the day of the
experiment. Mice were allowed to recover on a heating pad. After 5 days of
recovery, mice were subjected to clamp studies. The infusion studies lasted a
total of 90 min. At t  0 min, mice began receiving a constant infusion of
HPLC-puriﬁed [
3H]glucose (0.1 Ci/min; Perkin-Elemer), and insulin (3.5
mU/min/kg body weight; Humulin, Eli Lilly). A solution of glucose (20%) was
infused at a variable rate as required to maintain euglycemia (140–150 mg/dl).
Thereafter, plasma samples were collected to determine glucose levels (at t 
0, 30, 50, 60, 70, 80, and 90 min) as well as [
3H]glucose speciﬁc activity (at t 
0, 30, 50, 60, 70, 80, and 90 min). Plasma glucose was measured by the glucose
oxidase method (Glucose Analyzer, Analox GM-7 microstat).
Under steady-state conditions for plasma glucose concentration, the Rd
equals the rate of glucose appearance (Ra). Ra was determined from the ratio
of the infusion rate for [
3H]glucose (dpm) and the speciﬁc activity of plasma
[
3H]glucose (dpm) under steady-state conditions. The rate of glucose produc-
tion was therefore obtained from the difference between Ra and the rate of
glucose infusion.
Western blot analysis and immunoprecipitation procedures. Tissue
samples were homogenized in a Polytron (Brinkman Instruments, NY) in 20 ml
Tissue Protein Extraction Reagent /g of tissue according to the manufacturer’s
instructions (Pierce, IL). Immunoprecipitation and Western blot analysis have
been performed as previously described (26).
Real-time RT-PCR analysis. Total cellular RNA was isolated from liver
tissue and HepG2 cells by using the RNeasy kit (QIAGEN Sciences, Germany),
according to the manufacturer ‘s instructions. We reverse-transcribed 1 go f
tissue or cell RNA using Superscript II Reverse Transcriptase (Invitrogen, CA).
PCR reactions were analyzed using SYBR Green mix (Invitrogen, CA).
Reactions were performed using Platinum SYBR Green qPCR Super-UDG
using an iCycler IQ multicolor Real Time PCR Detection System (Biorad, CA).
All reactions were performed in triplicate and -actin was used as an internal
standard. Primer sequences used were as follows. G6Pase R 5-GTACCTCAG
GAAGCTGCCA-3, G6Pase F: 5-TTTGCTATTTTACGTAAATCACCCT-3, PEPCK
R5 -AATGTCATC ACCCACACA TTC- 3, PEPCK F: 5-ATG TATGTCATC CCA
TTC AGC- 3,PGC-1 R5 -AGGGTCATCGTTTGTGGTCAG-3, PGC-1 F
5CAGCGGTCTTAGCAC TCA G-3,h S y pR5 -GCTCTCAAAAGCCCTGTGTC-3,
hSyp F 5 GCTGGGACAAGCTGAAAGTC-3, hSHP1 R 5-GTCTCCAAACCAC
CCACTGT-3, hSHP1 F 5-GACGTTTCTTGTGCGTGAGA-3, hPTP1B R5-
GCTCTCAAAAGCCCTGTGTC-3, hPTP1B F 5-GCTGGGACAAGCTGAAAGTC-
3,m S y pR5 -TGCCCAGCGTCTCCACCATG-3,m S y pF5 -AGCAACGA
CGGCAAGTCCAAAG-3, mSHP1 R 5 TCCTCCGACTCCTGCTTCTTG 3, mSHP1
F5  GACCTGGTGGAGCACTTCAAG 3, mPTP1B R 5 CTCTATGCAACCCAAG
GAACTG 3, mPTP1B F 5 CTTCAGGTGGTGGAGACAGG 3, -actin F 5-
GCGTGACATCAAAGAGAAG-3 and -actin R 5-ACTGTGTTGGCATAGAGG-3.
Chromatin immunoprecipitation and luciferase assays. Chromatin im-
munoprecipitation (ChIP) and Re-ChIP assays were performed using nMuLi
cells as previously described (27). For luciferase assays, the mouse SHP1
fragment 1,887/335 (region n. 2) was ampliﬁed by PCR from genomic
mouse DNA isolated from the murine liver cell line (NmuLi cells). The
following primers were used: F: 5-KpnI- TCGGTGTGAGATCGGTACAA-3
and R:5-SacI- TCCGAGTTGGTGTCTCAGTG-3 (SHP1 n°2), (where SacI and
KpnI indicate the restriction sites added to the sequence). The ampliﬁed
fragments were cloned in the Plg3 promoter vector (Promega) by SacI and
KpnI. HeLa cells were cotransfected with 2 go fSHP1 n°2 promoter vector
together with different amounts of Prep1 and Pbx1 expression vectors. Total
DNA content (up to 4 g/plate) was normalized to the empty vector devoid of
Prep1 and Pbx1 coding sequence. Forty-eight hours after transfection, the
cells were harvested and lysed as described previously (27). Luciferase
activity was measured by a commercial luciferase assay kit (Promega). Values
were normalized for -galactosidase. Statistical signiﬁcance was evaluated by
t test analysis.
Statistical procedures. Data were analyzed with Statview software (Abacus
Concepts, Piscataway, NJ) by one-factor ANOVA. P values 	 0.05 were
considered statistically signiﬁcant (23).
RESULTS
Hepatic glucose metabolism in Prep1-deﬁcient mice.
To address the signiﬁcance of Prep1 to the insulin-resis-
tant and diabetic liver, we ﬁrst examined its expression in
high-fat diet-treated (HFD) and in diabetic db/db mice.
Hepatic expression of Prep1 was 37 and 67% higher,
respectively, in the HFD and db/db compared with the
control mice (Fig. 1A), suggesting a role of Prep1 in the
altered liver glucose metabolism and glucoregolatory func-
tion in the murine models. To investigate this issue in
greater detail, we compared liver glycogen and triglyceride
content in Prep1 hypomorphic mice (Prep1
i/; Prep1
i/i)
and in their nonhypomorphic littermates (wild type). Gly-
cogen content was signiﬁcantly increased in the hypomor-
phic mice and a Prep1 gene dosage effect was evidenced
(Fig. 1B; increases were twofold and threefold, respec-
tively, in the Prep1
i/ and the Prep1
i/i mice). At variance,
liver triglyceride content was reduced in the Prep1-deﬁ-
cient mice (3.3 
 1.7 and 14 mg/g 
 2.5 tissue, respec-
tively, in the Prep1
i/ and the nonhypomorphic mice) (Fig.
1C). However, no signiﬁcant difference was detected in
liver weight between Prep1 hypomorphic and wild-type
F. ORIENTE AND ASSOCIATES
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gluconeogenic enzymes G6Pase and PEPCK was, respec-
tively, 45 and 30% reduced in these mice compared with
controls, both at the mRNA and the protein levels (Fig. 1D;
P 	 0.01). We then measured liver sensitivity to insulin and
assessed glucose production by euglycemic hyperinsuline-
mic clamp in conscious Prep1 hypomorphic mice. In these
studies, the rate of insulin infusion was selected to gener-
ate a physiologic increase in plasma insulin (to 8 ng/ml) to
submaximally stimulate glucose uptake and inhibit glu-
cose production (28). As shown in Fig. 1E, basal glucose
production (mainly gluconeogenic after 16-h starvation)
was slightly but signiﬁcantly lower in the hypomorphic
mice. Insulin suppressed hepatic glucose production to
lower levels in Prep1
i/ mice (8 
 2.2 mg/kg/min) com-
pared with WT (15 
 3.1 mg/kg/min), reﬂecting enhanced
hepatic sensitivity to insulin. The increased hepatic sensi-
tivity to insulin in the hypomorphyc mice was further
supported by the higher glucose infusion rate (GIR) re-
quired to maintain euglycemia during the clamp (60 
 6
mg/kg/min in the Prep1
i/ vs. 40 mg/kg/min 
 6 in the WT)
(Fig. 1F).
The increased insulin sensitivity in muscle from Prep1
hypomorphic mice is largely contributed by reduced p160
stability, followed by higher PGC-1 levels in this tissue
(13). At variance with muscle, p160 abundance was very
low in liver and did not change in Prep1 hypomorphic
mice (Fig. 2A). PGC-1 levels also showed no change in
hypomorphic liver (Fig. 2B), suggesting that the action of
Prep1 on insulin sensitivity may involve different mecha-
nisms in liver and skeletal muscle. Also, at variance with
muscle (13), Pbx1 was abundantly expressed in liver from
WT mice but extremely reduced in those from their
Prep1-deﬁcient littermates (Fig. 2C).
Prep1 effect on the insulin signaling pathway in
mouse liver. To further analyze Prep1 action on liver
sensitivity to insulin, we ﬁrst proﬁled the initial steps of
the insulin-signaling cascade, both at the intracellular
abundance and at the activation levels. No change was
evidenced in either insulin receptor, IRS1 or IRS2 protein
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FIG. 1. Hepatic phenotype in HFD, db/db and in Prep1
i/ mice.A : Livers from WT, HFD, db/, and db/db mice were dissected, solubilized, and
Western blotted with anti-Prep1 antibodies. Blots were revealed by ECL and autoradiography and bands quantitated by laser densitometry and
normalized for actin. Each bar represents the mean  SD of duplicate determinations in seven mice per group. B: Prep1 hypomorphic and their
nonhypomorphic littermates (WT) were injected with insulin intraperitoneally (0.75 mU/g body weight). After 2 h, livers were isolated and
glycogen content was measured as described in RESEARCH DESIGN AND METHODS. Bars represent the means  SD of determinations in 12 mice per
group. C: Intrahepatic triglyceride content was measured as described in RESEARCH DESIGN AND METHODS. Bars represent the means  SD of
determinations in nine mice per group. D: G6Pase and PEPCK mRNA and protein content was determined by real-time RT-PCR analysis of total
RNA isolated from liver of Prep1
i/ and control mice injected with insulin for 1 h, using -actin as internal control. Bars represent the mean 
SD of four independent experiments, in each of which reactions were performed in triplicate using the pooled total RNAs obtained from six mice
per genotype. Glucose production (E) and glucose infusion rate (F) were assessed by euglycemic hyperinsulinemic clamp. All measurements were
performed during the ﬁnal 40 min of the 90-min clamp procedure, after steady-state conditions for plasma glucose and insulin concentrations,
glucose speciﬁc activity, and rates of glucose infusion were achieved as described in RESEARCH DESIGN AND METHODS. Asterisks denote statistically
signiﬁcant differences (*P < 0.05; **P < 0.01; ***P < 0.001).
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of these proteins was signiﬁcantly and gene dosage-depen-
dently increased in the hypomorphic mice. These changes
were accompanied by no change in the amount as well as
the phosphorylation of known negative regulators of the
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JNK, and GRB10 (data not shown). Interestingly, protein
levels of the tyrosine phosphatases SYP and SHP1 were
reduced, respectively, by threefold and twofold in the
Prep1
i/i mouse livers (Fig. 3B; P 	 0.001) and more
moderately in the Prep1
i/ mice. This reduction seemed at
least in part transcriptional as it was observed also at the
mRNA level and was speciﬁc for the two phosphatases
(Fig. 3C). Indeed, PTP1B tyrosine phosphatase levels
showed no difference in the hypomorphic mice and in their
nontransgenic littermates. Activation of the downstream
insulin pathway was also observed, with increased phos-
phorylation of both AKT and Foxo1 (data not shown).
Prep1 regulates insulin action in HepG2 cells. We
have transiently transfected a Prep1 cDNA in the HepG2
hepatoma cells. As shown in Fig. 4A, Prep1 overexpres-
sion almost completely prevented insulin-induced tyrosine
phosphorylation of the insulin receptor, IRS1 and IRS2. No
change was evidenced in the abundance of any of these
proteins. However, Prep1 transfection upregulated SYP
and SHP1 expression at both the mRNA and the protein
levels, but had no effect on PTP1B (Fig. 4B).
Prep1 transfection upregulated Pbx1 levels in the
HepG2 cells (Fig. 4A). Interestingly, transfection of the
Prep1HR1 mutant cDNA, which is unable to bind Pbx1 (12),
had no effect on either the phosphorylation of insulin
receptor, IRS1 and IRS2 or the levels of SYP and SHP1
tyrosine phosphatase (Fig. 4B). This indicates that the
Prep1-Pbx1 dimer controls insulin action in liver cells.
Consistent with this hypothesis, overexpression of a
Pbx1 cDNA in HepG2 cells mimicked Prep1 effects on
insulin-stimulated tyrosine phosphorylation of the insulin
receptor and IRS-1/2 (Fig. 5A), as well as on the level of
SYP and SHP1 (Fig. 5B). At variance, liver cell overexpres-
sion of the other major Prep1 partner, p160, elicited no
effect on these early steps in the insulin signaling cascade
(Fig. 5C). Importantly, transfection of the Prep1 or Pbx1
cDNAs, but not that of the Prep1HR1 mutant, abolished
insulin-induced glycogen accumulation in the HepG2 cells
(Fig. 5D). The failure of Prep1HR1 to mimic Prep1 effects
indicated that Prep1 action is exerted via dimerization
with Pbx1 rather than via p160.
SHP1 mediates the effect of Prep1 on insulin signal-
ing. To explore the signiﬁcance of SYP and SHP1 tyrosine
phosphatases to Prep1 regulation of insulin signaling in
liver, we have stable transfected a Prep1 full-length cDNA
in the HepG2 cells. Several clones were obtained, and
three of those, expressing increasing levels of Prep1, were
selected and further characterized (Fig. 6A). The
HepG2Prep1c clone overexpressed Prep1 by ﬁvefold and
featured a fourfold and threefold increased cellular con-
tent of SYP and SHP1, respectively (Fig. 6B). SYP and
SHP1 levels in the HepG2Prep1a and HepG2Prep1b cells
directly paralleled the lower level of Prep1 overexpression
in each clone (data not shown). Transient transfection of
the HepG2Prep1c cells with phosphorothioate antisense
oligonucleotides speciﬁc for SYP (SYP-AS) caused a 65%
reduction in SYP levels but elicited almost no change in
insulin-stimulated phosphorylation of the insulin receptor,
suggesting no change in insulin action in these cells (Fig.
6C). At variance, treatment with SHP1 antisense oligonu-
cleotides (SHP1-AS) silenced SHP1 by only 50% but in-
creased insulin receptor tyrosine phosphorylation by
almost threefold (Fig. 6D). Indeed, the impaired insulin-
dependent accumulation of glycogen observed in liver
cells overexpressing Prep1 was unaffected by SYP silenc-
ing but was rescued by the SHP1 AS (Fig. 6E). Thus, the
SHP1 gene mediates Prep1 control on insulin signaling in
the HepG2 hepatoma cells.
Prep1 regulation of SHP1 gene transcription. We
therefore examined the further possibility that Prep1
directly regulates SHP1 gene function. Bioinformatic anal-
ysis revealed the presence of several potential binding
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FIG. 4. Effect of the overexpression of Prep1 and Prep1HR1 mutant on
insulin signaling in HepG2 cells.A : HepG2 cells were transiently
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nmol/l insulin for 5 min. Cells were then solubilized and lysates were
immunoprecipitated with anti IR, IRS1, or IRS2 antibodies followed by
blotting with pY, IR, and IRS1 or IRS2 antibodies. Actin antibodies
were used for normalization. Bands were revealed by ECL and autora-
diography. The autoradiograph shown is representative of ﬁve inde-
pendent experiments. B: Lysates from HepG2 cells overexpressing
Prep1 or the Prep1HR1 mutant were blotted with SYP, PTP1B, and
SHP1 antibodies, followed by ECL and densitometry. Each bar repre-
sents the mean  SD of duplicate determinations in four independent
experiments. The levels of SYP, PTP1B, and SHP1 mRNAs in cells
transfected with the Prep1 and Prep1HR1 mutant cDNAs was quanti-
tated by real-time RT-PCR analysis, using  actin as internal standard.
Bars represent the mean  SD of four independent experiments.
Asterisks denote statistically signiﬁcant differences (**P < 0.01;
***P < 0.001).
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upstream the SHP1 transcription initiation site. By ChIP,
two of these sites bound Prep1 (Fig. 7A; positions nucle-
otide [nt] 2,489 to 2,139, nt 2,113 to 1,778), but
re-ChIP assays revealed that Pbx1 was simultaneously
present only at position nt 2,113 to 1,778. To investi-
gate whether this last region features enhancer activity,
we subsequently cloned this fragment in the pgl3 basic
construct upstream the luciferase gene (pgl3LUC). The
construct was then cotransfected in HeLa cells together
with the Prep1, Pbx1 cDNAs or both and luciferase
activity was measured (Fig. 7B). Prep1 and Pbx1 increased
the SHP1 reporter activity, respectively, by 7.1-fold and
6-fold. Simultaneous cotransfection of the two plasmids
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scriptional regulation by the Prep1/Pbx1 complex.
DISCUSSION
Previous studies have identiﬁed Prep1 as a physiologic
regulator of insulin-mediated glucose metabolism in skel-
etal muscle (13). In Prep1-deﬁcient mice, muscle sensitiv-
ity to insulin action on glucose disposal is signiﬁcantly
increased, due to downregulation of the major Prep1
partner p160 and induction of the GLUT4 gene activator
PGC-1  (13). In the present paper, we show that in
high-fat diet-treated or db/db mice, hepatic Prep1 levels
are increased, suggesting a role of Prep1 in controlling
insulin sensitivity and glucose metabolism in this organ as
well. Indeed, Prep1-deﬁcient mice showed increased he-
patic glycogen content and decreased glucose output and
triglyceride levels. Hypoinsulinemia, which represents a
prominent feature of the Prep1-deﬁcient mice (13), is
likely essential to enable these animals to maintain plasma
glucose levels only slightly below those of their nonhypo-
morphyc littermates. The mechanisms responsible for
Prep1 action in liver differ from those in the skeletal
muscle, however. First, at variance with muscle, Prep1
major functional partner in liver appears to be Pbx1 rather
than p160. We have shown that in this organ, Prep1
expression determines Pbx1 levels as Prep1-hypomorphic
mice exhibit a very signiﬁcant reduction of liver Pbx1.
Importantly, Pbx1 mimics Prep1 action on glycogen con-
α α-Prep1
HepG2
HepG2Prep1A
HepG2Prep1B
HepG2Prep1C
A
C
D
HepG2Prep1C HepG2
α-SYP
α-SHP1
α-actin
B
α-SYP
α-actin
- +        - +     insulin
E
I.P.α-IR
W.B. α-pY
I.P.α-IR
W.B. α-IR
0
20
40
60
80
100
- + insulin
G
l
y
c
o
g
e
n
 
C
o
n
t
e
n
t
(
µ
g
/
m
g
 
p
r
o
t
e
i
n
)
- + - + - +
SYP
SC
SYP
AS
SHP1
SC
SHP1
AS
SYP SC SYP AS
**
- +        - +     insulin
SHP1 SC SHP1 AS
α-SHP1
α-actin
I.P .α-IR
W.B. α-pY
I.P .α-IR
W.B. α-IR
FIG. 6. Effect of SYP and SHP1 antisense oligonucleotides on insulin signaling in HepG2 cells stable transfected with Prep1. A: HepG2 cells were
stable transfected with a Prep1 cDNA, as described under RESEARCH DESIGN AND METHODS. Clones of cells expressing varying levels of Prep1
(HepG2Prep1A, HepG2Prep1B, HepG2Prep1C) and the untransfected cells (HepG2) were analyzed by immunoblotting with Prep1 antibodies and
autoradiography. B: Lysates from HepG2or HepG2Prep1c cells were analyzed by immunoblotting with SYP, SHP1 or actin antibodies followed by
ECL and autoradiography. C and D: HepG2or HepG2Prep1c cells were transfected with SYP (SYP-AS) (C)o rSHP1 (SHP1-AS) (D) speciﬁc
phosphorothioate antisense oligonucleotides, stimulated with 100 nmol/l insulin for 5 min and immunoprecipitated with insulin receptor
antibodies followed by blotting with either pY or IR antibodies. For control, identical aliquots of the lysates were also blotted with SYP, SHP1,
or actin antibodies. Bands were revealed by ECL and autoradiography as reported under RESEARCH DESIGN AND METHODS. The autoradiographs shown
are representative of four independent experiments. E: The HepG2Prep1c cells were transfected with SYP-AS and the SHP1-AS and further
stimulated with 100 nmol/l insulin for 5 min. Glycogen content was then assayed as described under RESEARCH DESIGN AND METHODS. Bars represent
mean values  SD of determinations in four independent experiments, each in duplicate. Asterisks denote statistically signiﬁcant differences
(**P < 0.01).
PREP1 AND LIVER GLUCOREGULATORY FUNCTION
144 DIABETES, VOL. 60, JANUARY 2011 diabetes.diabetesjournals.orgtent in hepatocytes, whereas p160, which is expressed at
very low levels in this cell type and is not regulated by
Prep1, does not. Second, Prep1 does not induce repression
of PGC-1 levels in the liver cells. Indeed, the repression
of PGC-1 occurring in skeletal muscle is achieved by
Prep1 increase in p160 half-life which directly represses
PGC-1 (13). Foxo1 nuclear localization is a major event
determining PGC-1 induction of the key gluconeogenetic
genes G6Pase and PEPCK (17). In Prep1-hypomorphic
mice, Akt as well as Foxo1 phosphorylation is increased,
indicating induced nuclear export (data not shown). We
suggest that the reduced nuclear abundance of Foxo1
may, at least in part, explain how the upregulated insulin
signaling observed in Prep1
i/i mice downregulates G6Pase
and PEPCK gene transcription in the presence of unal-
tered PGC-1 levels.
Analysis of the initial steps in insulin signaling in the
Prep1-deﬁcient mouse liver revealed increased tyrosine
phosphorylation of both insulin receptor and the major
IRSs present in these cells. Interestingly, although no
change in the intracellular levels of these proteins was
detected, the levels of both the SYP and SHP1 tyrosine
phosphatases were found signiﬁcantly decreased in Prep1-
hypomorphic mouse liver and underwent opposite
changes in cultured liver cells transiently transfected with
a Prep1 cDNA. Previously published data from gene
knockout and transgenic overexpression models have
identiﬁed an important role of phosphotyrosine phospha-
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homeostasis in vivo (19,20,22). The PTP1B phosphoty-
rosine phosphatase has received particular attention as
genetic and biochemical ﬁndings indicate a key inhibitory
role for PTP1B in modulating insulin signaling (29,30).
However, PTP1B levels were unaffected both in liver
tissue from Prep1-deﬁcient mice and in cells overexpress-
ing Prep1, indicating speciﬁcity in Prep1 control of phos-
photyrosine phosphatase. More recent studies in SHP1-
deﬁcient mice have shown an important role for SHP1 in
the modulation of insulin sensitivity and glucose metabo-
lism at the whole-body as well as liver levels (31). In this
study, the functional relevance of Prep1 control of SHP1
versus SYP expression to hepatic sensitivity to insulin was
assessed in further experiments in HepG2 liver cells stable
transfected with Prep1. These cells feature a very signiﬁ-
cant reduction of insulin effect on glycogen accumulation.
However, antisense silencing of SHP1, though not of SYP,
rescued insulin effect in these cells, thus establishing SHP1
as the functionally relevant target of Prep1 in the liver.
Previous in vitro and in vivo studies of SHP1 function have
identiﬁed the insulin receptor as the primary target of
SHP1 action in the upstream insulin signaling cascade
(31,32). Based on this information, we propose that en-
hanced insulin action in the liver of Prep1-deﬁcient mice
results from reduced SHP1-insulin receptor binding and
attenuated dephosphorylation with secondary activation
of the IRS system.
SHP1 downregulation in liver tissue from the Prep1-
hypomorphic mice occurred both at the protein and at the
mRNA levels, raising the possibility that Prep1 acts, at
least in part, by regulating SHP1 gene expression. Indeed,
we show that the regulatory region of SHP1 gene contains
several Prep1 binding sites in the 4,000 base-pair region
upstream SHP1 transcription initiation site and one Prep1/
Pbx1 binding site responding to the ectopic expression of
Prep1 and Pbx1 in cotransfection experiments in vitro. In
these assays, a fragment containing single Prep1/Pbx1
binding site displays a powerful enhancer function. In
addition, ChIp experiments with Prep1 and Pbx1 antibod-
ies showed that these proteins bind the SHP1 regulatory
region, suggesting that SHP1 gene is a target of the
Prep1/Pbx1 complex and not just Prep1. However, since
Pbx1 increases the nuclear localization of Prep1 (7,8), it is
also possible that the forced expression of Pbx1 causes
the nuclear accumulation of Prep1, thereby enhancing its
transcriptional effect on SHP1.
At variance with the liver, in muscle cells, the prevalent
association of Prep1 with p160, rather than with Pbx1, may
account for the lack of signiﬁcant SHP1 upregulation by
Prep1 (data not shown) and the reported lower abundance
of SHP1, particularly in the nuclear compartment of mus-
cle cells (33,34). Thus, at least in part, different partners
may account for the tissue speciﬁcity in Prep1 regulatory
functions. Variation in Prep1 action in the major insulin-
responsive tissues are likely relevant to the phenotype of
Prep1-hypomorphic and are paralleled by the phenotype
of SHP1-deﬁcient mice. Both of these mice are markedly
glucose tolerant and insulin sensitive, at both muscle and
hepatic levels (31,13). In both mouse models, SHP1 down-
regulation causes improved insulin-dependent suppres-
sion of hepatic glucose output. However, the enhanced
peripheral (muscle) sensitivity to insulin in the SHP1-
deﬁcient mice is further contributed by p160 repression in
the Prep1-hypomorphic mouse muscles (13).
In conclusion, we have identiﬁed the SHP1 tyrosine
phosphatase, a known negative regulator of insulin signal-
ing, as a novel transcriptional target of Prep1. In the liver,
Prep1 silencing enhances insulin signaling, thereby in-
creasing glucose storage and reducing glucose output.
This effect might be further ampliﬁed by the reduction in
glucagon levels which also occurs in Prep1 hypomorphic
mice (13). Indeed, these mice feature a slower recovery
from insulin-induced hypoglycemia when compared with
their nonhypomorphic littermates, and they appear to
continue to accumulate glycogen (13). The ﬁndings re-
ported in the present paper might have clinical relevance
as preliminary evidence in our laboratory indicates that
Prep1 gene is overexpressed in euglycemic offspring of
type 2 diabetic individuals. These subjects have a very high
risk of diabetes (35) and are known to be insulin resistant,
suggesting that Prep1 overexpression may provide an
early contribution to diabetes progression in these individ-
uals. Whether and how genetic variability at the Prep1
locus affects glucose tolerance in humans is an important
issue that deserves to be investigated in detail.
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